The Scientific Evidence

This content is for informational purposes only and does not constitute medical or nutritional advice. Speak with your health professional before starting this protocol.

Note: The studies summarised here were conducted across varied populations under different conditions. Results shown represent group averages — individual outcomes will differ. This content is intended to provide scientific context, not to predict your personal results.

The Research Is There

The Fat Loss Sprint is not a new idea. The VLCD and PSMF protocols behind it have been studied for over fifty years, with hundreds of published studies including randomized controlled trials, systematic reviews, meta-analyses, and large clinical case series. This chapter reviews that evidence: where it started, what the major studies found, and what the data says about safety.

The Foundational Research: 1970–1985

Blackburn and Bistrian Build the Protocol

In the early 1970s, George L. Blackburn, MD, PhD, and Bruce R. Bistrian, MD, PhD, at Harvard Medical School developed the Protein Sparing Modified Fast. Blackburn had observed that hospitalized patients receiving intravenous protein solutions maintained better nitrogen balance and recovered more effectively than those who did not. He applied the same principle to outpatient obesity treatment: provide protein sufficient to maintain nitrogen balance, restrict total energy intake, monitor patients closely (Blackburn et al., 1973).

The resulting protocol used 650–800 kcal per day from lean meat, fish, and poultry, delivering 1.2–1.5 g of protein per kg of ideal body weight. Carbohydrates and fat were minimized. Patients received potassium, a multivitamin, and other essential micronutrients, with regular blood work and clinical monitoring (Bistrian et al., 1976).

Initial Clinical Results

The early clinical findings were compelling. In their 1976 study of obese patients with type 2 diabetes on the PSMF (Bistrian et al., 1976):

• Exogenous insulin requirements were withdrawn after a mean of 6.5 days
• Blood glucose fell significantly
• Nitrogen balance was maintained with protein intake of at least 1.3 g/kg ideal body weight
• Weight loss was substantial and consistent

In 1978, Bistrian published a comprehensive review in JAMA establishing the PSMF as a distinct clinical protocol, explicitly differentiated from total fasting and from commercial liquid protein products. The protocol specified high biological value protein, electrolyte supplementation, clinical monitoring, a defined target population, and a structured duration of 12–16 weeks (Bistrian, 1978).

The 668-Patient Case Series (Palgi et al., 1985)

The landmark large-scale study was published in the American Journal of Public Health by Palgi, Read, Greenberg, Hoefer, Bistrian, and Blackburn. It followed 668 outpatients on a multidisciplinary PSMF program at New England Deaconess Hospital.

Key findings:

• Mean weight loss: 18.6 kg (41 lbs) over a mean treatment duration of 17 weeks
• More than 50% of patients lost over 9 kg (20 lbs)
• More than 33% lost over 18 kg (40 lbs)
• Significant reductions in systolic and diastolic blood pressure, and in serum triglycerides
• Favorable safety profile with appropriate monitoring
• The program included nutrition education, behavior modification, exercise instruction, and group support

This remains one of the largest published case series of a PSMF-based intervention. It demonstrated the protocol was viable at scale in an outpatient clinical setting.

Nitrogen Balance Studies

The scientific foundation of the PSMF rests on nitrogen balance research demonstrating that adequate protein preserves lean mass during severe restriction.

Bistrian et al. (1976): Protein intake of 1.3–1.5 g/kg ideal body weight maintained nitrogen equilibrium in obese diabetic patients on a PSMF providing fewer than 800 kcal/day.

Hoffer et al. (1984): Detailed nitrogen balance studies in obese subjects showed that 1.5 g/kg ideal body weight of protein produced nitrogen equilibrium, while lower intakes resulted in progressive negative nitrogen balance and lean tissue loss.

The Liquid Protein Crisis

What Happened

Any serious review of VLCD evidence must address the liquid protein disaster of the late 1970s, because it shaped public and clinical perception of the protocol for decades.

In 1976, osteopath Robert Linn published The Last Chance Diet, promoting a product called Prolinn: a liquid protein supplement made from predigested collagen, providing ~300–400 kcal/day. It was deficient in essential amino acids, contained no electrolyte supplementation, and was marketed directly to consumers without medical supervision (Linn, 1976).

Millions of Americans used it. By 1979, Isner et al. published a landmark case series in Circulation documenting 17 deaths among users (Isner et al., 1979). The deaths were characterized by:

• Prolonged QT interval on ECG
• Ventricular tachycardia and fibrillation
• Myocardial atrophy at autopsy

Sours et al. (1981) expanded the investigation, identifying the primary risk factors: protein of low biological value, no electrolyte supplementation (particularly potassium), no medical monitoring, and extended unsupervised use.

Why This Does Not Apply to the Fat Loss Sprint

The scientific response was unambiguous. The deaths were attributable to specific, identifiable causes, not to the concept of very low calorie dieting (Bistrian, 1978; Wadden et al., 1990).

Note on caloric intake: Classic PSMF protocols ran at 400–800 kcal/day. The Fat Loss Sprint enforces a hard 800 kcal floor. This is a deliberate safety modification: the cardiac deaths from the 1970s liquid protein products occurred at sub-400 kcal intake with no electrolyte support; even properly supervised Classic PSMF studies operated at the low end of that range. FLS adds an 800 kcal minimum and required electrolyte intake (food first, with capsules as a top-up) as twin safeguards.

The liquid protein crisis triggered decades of guilt-by-association toward all forms of very low calorie dieting. That association was not scientifically justified then, and it is not justified now.

The Modern Evidence Base: 1990–Present

Tsai and Wadden: The Evolution of VLCDs (2006)

This meta-analysis in Obesity analyzed VLCD evidence from the 1980s through the mid-2000s (Tsai & Wadden, 2006).

Short-term weight loss: VLCDs produced significantly greater short-term weight loss than conventional low-calorie diets: 16.1 ± 1.6% vs. 9.7 ± 2.4% of initial body weight (P = 0.0001).

Long-term maintenance: At one year or beyond, the difference narrowed and was no longer statistically significant: 6.3 ± 3.2% vs. 5.0 ± 4.0% (P > 0.2). This convergence was primarily due to weight regain in both groups over time.

Safety: The modern VLCD, using high-quality protein and supervised electrolyte supplementation, demonstrated an acceptable safety profile. Attrition rates were similar between VLCD and LCD groups.

The right interpretation: This meta-analysis is often cited as evidence that VLCDs offer no advantage over conventional dieting. That reading misses something important. If both approaches produce similar long-term results but the VLCD produces faster initial results, greater immediate health improvements, and better adherence in many populations, the VLCD may actually be the superior choice for specific individuals. Both approaches converge over time, not because fast approaches fail, but because long-term maintenance is hard for everyone.

Purcell et al.: Rate of Weight Loss and Long-Term Management (2014)

This randomized controlled trial in The Lancet Diabetes & Endocrinology directly tested whether rapid weight loss leads to greater weight regain than gradual weight loss (Purcell et al., 2014).

Design: 200 adults with obesity were randomized to either:

• Rapid weight loss: 12-week VLCD (450–800 kcal/day) targeting 15% weight loss
• Gradual weight loss: 36-week LCD (~500 kcal/day deficit) targeting the same 15%

Both groups who achieved at least 12.5% weight loss entered a 144-week maintenance phase.

Key findings:

• Rapid group: 81% achieved the 12.5% target
• Gradual group: 50% achieved the 12.5% target
• Dropout during active phase: 3% (rapid) vs. 18% (gradual)
• Weight regain during maintenance was similar in both groups (~71% of lost weight regained by week 144)
• The proportion of weight regained did not differ between groups

Conclusion: Rate of weight loss does not determine rate of weight regain. The rapid approach produced more people achieving clinically significant weight loss, and retained more participants through the protocol.

Five-Year PSMF Outcomes (Muralidhara et al., 2020)

A retrospective study in Obesity examined five-year weight outcomes in 1,403 patients who started a PSMF versus patients using other dietary approaches at a university-based weight management clinic (Muralidhara et al., 2020).

Key findings:

• At one year: 55% of PSMF patients achieved at least 5% weight loss vs. 20% of the comparison group (P < 0.001)
• At three years: 33% of PSMF patients maintained at least 5% loss vs. 23% of comparison group (P < 0.05)
• At five years: 34% vs. 29% (P = 0.16, no longer statistically significant)
• In the adjusted analysis, PSMF patients averaged 3% more total weight loss over 5 years (95% CI: −3.5, −2.0; P < 0.001)

The PSMF group was never worse than the comparison group at any time point. This directly contradicts the assumption that rapid weight loss produces worse long-term outcomes.

Willoughby, Hewlings, and Kalman: Exercise and Protein During VLCDs (2023)

A 2023 review in Current Opinion in Clinical Nutrition and Metabolic Care examined the role of exercise and protein in preserving skeletal muscle during VLCDs (Willoughby et al., 2023).

Key conclusions:

• VLCDs are effective for rapid fat loss but carry a risk of lean mass reduction
• Resistance exercise training is the most effective strategy for maintaining muscle mass during a VLCD
• Adequate protein intake (at least 1.2 g/kg/day) combined with resistance training substantially mitigates lean mass loss
• The combination of high protein and resistance training has the strongest evidence base for lean mass preservation during severe restriction

This reinforces the two core components of the protocol: high protein intake and resistance training.

VLCKD Meta-Analysis: Caprio et al. (2020)

A systematic review and meta-analysis of 12 studies examined very low-calorie ketogenic diets in patients with overweight and obesity (Caprio et al., 2020).

Key findings:

• VLCKD produced weight losses of 10.0 kg for ketogenic phases up to four weeks, and 15.6 kg for phases of at least four weeks
• Weight lost during the ketogenic phase was maintained at follow-up for up to two years (P = 0.12 for regain)
• Significant reductions in BMI (−5.3 kg/m²), waist circumference (−12.6 cm), HbA1c (−0.7%), and total cholesterol (−28 mg/dL)
• Safety profile was acceptable; the most common side effects were transient (constipation, headache, mild fatigue)

European Guidelines (Muscogiuri et al., 2021)

The European Association for the Study of Obesity published formal guidelines for obesity management using VLCKD, based on a systematic review of the literature (Muscogiuri et al., 2021).

Key recommendations:

• VLCKD is an effective dietary treatment for individuals with obesity
• Particularly recommended for severe obesity and/or comorbidities including joint disease, pre-bariatric surgery, and cardiovascular or metabolic disease
• Should be administered under healthcare professional supervision
• Contraindicated in pregnancy, breastfeeding, type 1 diabetes, significant liver or kidney disease, and active eating disorders
• Monitoring should include regular blood chemistry, electrolytes, and clinical assessment

VLCDs and Type 2 Diabetes

Two systematic reviews have specifically examined VLCD use in type 2 diabetes:

Rehackova et al. (2016): VLCDs were associated with significant weight loss, improved glycemic control (reduced fasting glucose and HbA1c), improved cardiovascular risk profiles, high tolerability, and favorable safety outcomes.

Sellahewa et al. (2022): VLCDs significantly improved fasting glucose (pooled mean difference −1.51 mmol/L; 95% CI −2.89, −0.13; P = 0.03) and HbA1c (−0.66%; 95% CI −1.28, −0.03; P = 0.04) compared to non-dietary therapy.

The DiRECT trial used a structured LCD/VLCD total diet replacement program and achieved type 2 diabetes remission in 46% of participants at one year and 36% at two years, far exceeding standard care outcomes (Lean et al., 2018; Lean et al., 2019).

Safety: What the Evidence Actually Shows

The Modern Protocol's Safety Profile

The modern VLCD/PSMF, when properly designed and followed as directed, has a favorable safety profile. The cardiac dangers associated with the 1970s liquid protein products have been entirely addressed by:

1. High biological value protein from whole food sources or well-formulated supplements
2. Mandatory electrolyte supplementation (sodium, potassium, magnesium)
3. Regular clinical monitoring
4. Structured duration limits (typically 2–16 weeks in the broader VLCD/PSMF clinical literature; the Fat Loss Sprint uses fixed durations of 14, 21, or 28 days determined by Sprint Level)
5. Medical screening to exclude contraindicated populations

Common Side Effects

Transient and mild (typically resolving within 1–2 weeks):

• Constipation (from reduced food volume and lower fibre)
• Headache (first 2–5 days, resolving with ketoadaptation)
• Fatigue and dizziness (first week)
• Cold sensitivity (from reduced dietary thermogenesis)
• Bad breath (acetone during ketosis)
• Mild hair thinning (telogen effluvium, typically reversible when calories are restored)
• Muscle cramps (electrolyte-related; resolved with supplementation)

Uncommon but documented:

• Gallstone formation (associated with rapid weight loss generally, not specifically to VLCDs; risk mitigated by including a small amount of dietary fat)
• Gout flares (ketosis-related hyperuricemia; transient)

Not observed in modern properly designed protocols:

• Cardiac arrhythmias
• Myocardial atrophy
• Death attributable to the diet

Adherence and Dropout

Attrition in VLCD studies is generally comparable to conventional dietary interventions. In the Tsai & Wadden (2006) meta-analysis, dropout rates in VLCD groups were similar to LCD groups. Muscogiuri et al. (2021) reported adherence rates of 69–93% across VLCD studies. The ketogenic nature of the Fat Loss Sprint may actually improve adherence compared to low-fat VLCDs, because ketosis suppresses appetite (Paoli et al., 2015).

Key Findings

• Palgi et al. (1985): The largest published PSMF case series (668 patients) demonstrated mean weight loss of 18.6 kg over 17 weeks with significant improvements in blood pressure and triglycerides.
• Purcell et al. (2014): 81% of the rapid weight loss group achieved clinically significant weight loss vs. only 50% of the gradual group. Weight regain during maintenance was identical between groups.
• Caprio et al. (2020): Meta-analysis of 12 VLCKD studies showed weight loss of 10–15.6 kg with stable maintenance for up to 2 years and significant metabolic improvements.

Summary

• The Fat Loss Sprint protocol has a research history spanning over fifty years, beginning with Blackburn and Bistrian at Harvard Medical School in the 1970s.
• Nitrogen balance studies established that Classic PSMF protein intake of 1.2–1.5 g/kg ideal body weight preserves lean mass during severe restriction. The Fat Loss Sprint raises this to 2.2–3.0 g/kg lean body mass — a higher and more precise target — because LBM-based calculations are more accurate and higher absolute protein better protects muscle under severe restriction.
• The 1970s liquid protein deaths resulted from specific, identifiable factors (low-quality protein, no electrolytes, no supervision) that are entirely absent from the properly designed protocol.
• Modern meta-analyses and RCTs confirm that VLCDs produce greater short-term weight loss than conventional diets, with similar long-term maintenance outcomes.
• The protocol has been shown to be safe and effective across multiple populations including adults with severe obesity, type 2 diabetes, adolescents, and pre-bariatric surgery patients.
• Lean mass preservation is optimized through the combination of high protein intake and resistance training.
• The evidence does not support the claim that rapid weight loss is inherently more dangerous, less effective, or more likely to result in weight regain.

References

• Bakhach, M., Shah, V., Harwood, T., Lappe, S., Bhesania, N., Mansoor, S., & Alkhouri, N. (2016). The Protein-Sparing Modified Fast Diet: An effective and safe approach to induce rapid weight loss in severely obese adolescents. Global Pediatric Health, 3, 2333794X15623245. https://doi.org/10.1177/2333794X15623245
• Bistrian, B. R. (1978). Clinical use of a protein-sparing modified fast. JAMA, 240(21), 2299–2302. https://doi.org/10.1001/jama.1978.03290210069032
• Bistrian, B. R., Blackburn, G. L., Flatt, J. P., Sizer, J., Scrimshaw, N. S., & Sherman, M. (1976). Nitrogen metabolism and insulin requirements in obese diabetic adults on a protein-sparing modified fast. Diabetes, 25(6), 494–504. https://doi.org/10.2337/diab.25.6.494
• Blackburn, G. L., Flatt, J. P., Clowes, G. H., O'Donnell, T. F., & Hensle, T. E. (1973). Protein sparing therapy during periods of starvation with sepsis or trauma. Annals of Surgery, 177(5), 588–594. https://pubmed.ncbi.nlm.nih.gov/4633412/
• Caprio, M., Infante, M., Moriconi, E., Armani, A., Fabbri, A., Mantovani, G., et al. (2020). Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: A systematic review and meta-analysis. Reviews in Endocrine and Metabolic Disorders, 21(1), 5–16. https://doi.org/10.1007/s11154-019-09514-y
• Hoffer, L. J., Bistrian, B. R., Young, V. R., Blackburn, G. L., & Matthews, D. E. (1984). Metabolic effects of very low calorie weight reduction diets. The Journal of Clinical Investigation, 73(3), 750–758. https://doi.org/10.1172/JCI111268
• Isner, J. M., Sours, H. E., Paris, A. L., Ferrans, V. J., & Roberts, W. C. (1979). Sudden, unexpected death in avid dieters using the liquid-protein-modified-fast diet. Circulation, 60(6), 1401–1412. https://doi.org/10.1161/01.CIR.60.6.1401
• Lean, M. E. J., Leslie, W. S., Barnes, A. C., et al. (2018). Primary care-led weight management for remission of type 2 diabetes (DiRECT). The Lancet, 391(10120), 541–551. https://doi.org/10.1016/S0140-6736(17)33102-1
• Lean, M. E. J., Leslie, W. S., Barnes, A. C., et al. (2019). Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT trial. The Lancet Diabetes & Endocrinology, 7(5), 344–355. https://doi.org/10.1016/S2213-8587(19)30068-3
• Muralidhara, D. V., Engel, S. G., Engel, H., & Crosby, R. D. (2020). The effect of starting the protein-sparing modified fast on weight change over 5 years. Obesity, 28(2), 289–296. https://pubmed.ncbi.nlm.nih.gov/31916212/
• Muscogiuri, G., El Ghoch, M., Colao, A., Hassapidou, M., Yumuk, V., & Busetto, L. (2021). European guidelines for obesity management in adults with a very low-calorie ketogenic diet. Obesity Facts, 14(2), 222–245. https://doi.org/10.1159/000515381
• Palgi, A., Read, J. L., Greenberg, I., Hoefer, M. A., Bistrian, B. R., & Blackburn, G. L. (1985). Multidisciplinary treatment of obesity with a protein-sparing modified fast: Results in 668 outpatients. American Journal of Public Health, 75(10), 1190–1194. https://doi.org/10.2105/AJPH.75.10.1190
• Paoli, A., Bosco, G., Camporesi, E. M., & Mangar, D. (2015). Ketosis, ketogenic diet and food intake control. Frontiers in Psychology, 6, 27. https://doi.org/10.3389/fpsyg.2015.00027
• Purcell, K., Sumithran, P., Prendergast, L. A., Bouniu, C. J., Delbridge, E., & Proietto, J. (2014). The effect of rate of weight loss on long-term weight management: A randomised controlled trial. The Lancet Diabetes & Endocrinology, 2(12), 954–962. https://doi.org/10.1016/S2213-8587(14)70200-1
• Rehackova, L., Arnott, B., Engel, H., Sherrington, E., & Peters, S. (2016). A systematic review of evidence on the use of very low calorie diets in people with diabetes. Nutrition & Dietetics, 73(5), 453–460. https://pubmed.ncbi.nlm.nih.gov/26435354/
• Sellahewa, L., Khan, C., Lakkunarajah, S., & Idris, I. (2022). Investigating the effectiveness of very low-calorie diets and low-fat vegan diets on weight and glycemic markers in type 2 diabetes mellitus: A systematic review and meta-analysis. Nutrients, 14(22), 4870. https://doi.org/10.3390/nu14224870
• Sours, H. E., Frattali, V. P., Brand, C. D., et al. (1981). Sudden death associated with very low calorie weight reduction regimens. The American Journal of Clinical Nutrition, 34(4), 453–461. https://doi.org/10.1093/ajcn/34.4.453
• Thomas, D. D., Istfan, N. W., Bistrian, B. R., & Apovian, C. M. (2018). Protein sparing therapies in acute illness and obesity: A review of George Blackburn's contributions to nutrition science. Metabolism, 79, 83–96. https://doi.org/10.1016/j.metabol.2017.11.020
• Tsai, A. G., & Wadden, T. A. (2006). The evolution of very-low-calorie diets: An update and meta-analysis. Obesity, 14(8), 1283–1293. https://doi.org/10.1038/oby.2006.146
• Wadden, T. A., Van Itallie, T. B., & Blackburn, G. L. (1990). Responsible and irresponsible use of very-low-calorie diets in the treatment of obesity. JAMA, 263(1), 83–85. https://doi.org/10.1001/jama.1990.03440010081039
• Willoughby, D., Hewlings, S., & Kalman, D. (2023). The impact and utility of very low-calorie diets: The role of exercise and protein in preserving skeletal muscle mass. Current Opinion in Clinical Nutrition and Metabolic Care, 26(6), 521–528. https://doi.org/10.1097/MCO.0000000000000980